Search Results - Emma Moore
- Showing 1 - 10 results of 10
-
1
Krebspatienten können nicht warten by Murray Aitken, Emma Moore
Published in Monitor Versorgungsforschung (2021-08-01)Get full text
Article -
2
-
3
-
4
-
5
5 CLABSI prevention with secure chat messaging by Emma Moore, Celina Santiago, Nicole Burton, Molly Kratz, Leah Seifu, Tristan McPherson, William Greendyke, Elise Mantell
Published in Antimicrobial Stewardship & Healthcare Epidemiology (2026-08-01)Get full text
Article -
6
Acceptability, use and safety of the BlueIce self-harm prevention app: qualitative findings from the Beating Adolescent Self-Harm (BASH) randomised controlled trial by Gordon Taylor, Emma Moore, Antonieta Medina-Lara, Shelley Rhodes, Paul Stallard, Nia Morrish, Bethany Cliffe, Kathryn Whittle
Published in BMJ Mental Health (2024-05-01)Get full text
Article -
7
Estimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS Part III by Dylan Trundell, Evan W. Davies, Louise Barrett, Stefano Zanigni, Nima Shariati, Rebecca Rogers, Annabelle Monnet, Emma Moore, Nathalie Pross, Gennaro Pagano, Stefan Cano, Tania Nikolcheva
Published in Journal of Parkinson’s Disease (2025-02-01)Get full text
Article -
8
Long-Term Safety of PEGylated Coagulation Factor VIII in the Immune-Deficient Rowett Nude Rat by Caroline E. Rasmussen, Jette Nowak, Julie M. Larsen, Emma Moore, David Bell, Kai Chiu Liu, Nanna Skall Sorensen, Wendela A. Kappers, Thomas Krogh-Meibom, Hanne Offenberg
Published in Journal of Toxicology (2017-01-01)Get full text
Article -
9
Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials by Gennaro Pagano, Dylan Trundell, Tanya Simuni, Nicola Pavese, Kenneth Marek, Ronald B. Postuma, Nima Shariati, Annabelle Monnet, Emma Moore, Evan W. Davies, Hanno Svoboda, Nathalie Pross, Azad Bonni, Tania Nikolcheva, for the PASADENA Investigators, Prasinezumab Study Group
Published in npj Parkinson's Disease (2025-08-01)Get full text
Article -
10
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials by Gennaro Pagano, Dylan Trundell, Tanya Simuni, Nicola Pavese, Kenneth Marek, Ronald B. Postuma, Nima Shariati, Annabelle Monnet, Emma Moore, Evan W. Davies, Hanno Svoboda, Nathalie Pross, Azad Bonni, Tania Nikolcheva, for the PASADENA Investigators, Prasinezumab Study Group
Published in npj Parkinson's Disease (2025-07-01)Get full text
Article
